NEW YORK (360Dx) — Clinical contract research firm Galaxy announced on Tuesday its launch, as well as a licensing deal for intellectual property covering blood-based biomarkers of stroke from Proteome Sciences.
According to McKinney, Texas-based Galaxy, the IP was generated by Proteome Sciences in partnership with the University of Geneva and Geneva University Hospitals, and will be used in the development of a point-of-care test for the diagnosis and timing of stroke onset to help inform treatment decisions.
In exchange for the license, Proteome Sciences will receive an undisclosed equity stake in Galaxy and stands to receive future milestones and royalties. Additional terms were not disclosed.
While Proteome Sciences had for years worked with research groups on stroke-related biomarkers, generating data that suggested diagnostics might be able to pinpoint the time of stroke, about two years ago the UK-based firm began to shift its focus onto its pharmaceutical services offerings.